|
Gilead’s Vitekta Gets Approval in European Union
Wall Street Journal Meanwhile, Gilead said its Phase 3 study of idelalisib in combination with rituximab in previously treated chronic lymphocytic leukemia patients who weren’t fit for chemotherapy was accepted for presentation at the Annual Meeting of the American … |
|
Investing Ideas from the Cutting Edge of Biotech
Kapitall Blog (blog) It has a potentially better follow-on to Roche/Genentech’s old monoclonal antibody Rituxan (rituximab). Roche’s monoclonal antibody Gazyva (obinutuzumab; GA101) was recently approved and we believe provides important validation to TG’s ublituximab, … |
NIH Study Finds Low-Intensity Therapy For Burkitt Lymphoma Is Highly EffectiveRedOrbitNineteen HIV-negative patients received dose-adjusted (DA)-EPOCH-R, whereas 11 HIV-positive patients received SC-EPOCH-RR, which is a short-course (SC) variant of EPO…
|
Cyclophosphamide and rituximab combo reduced severe lupus flares
Skin and Allergy News Digital Network SAN DIEGO – The combination of intravenous cyclophosphamide and rituximab shows promise for the reduction of lupus flares, both renal and nonrenal, in patients with severe systemic lupus erythematosus, according to Dr. Ali Shahzad. Moreover, this … |
INNATE PHARMA : preclinical data opening new perspectives for development …GlobeNewswire (press release)Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated, antibody-depende…
|
Low-Dose Therapy for Burkitt’s Passes Muster
MedPage Today Investigators examined two similar regimens: standard dose-adjusted EPOCH-R (DA-EPOCH-R) for HIV-negative patients and short-course therapy with a double dose of rituximab (SC-EPOCH-RR). Patients treated with DA-EPOCH-R continued therapy for … NIH study finds low-intensity therapy for Burkitt lymphoma is highly effectiveEurekAlert (press release) Low-intensity chemo works for Burkitt’s lymphomaThe Oncology Report Low-intensity EPOCH-R regimen effective in immunodeficiency-associated …Healio |
|
TG Therapeutics, Inc. (TGTX): TG Therapeutics’ CEO Discusses Q3 2013 Results …
Seeking Alpha The third preclinical poster will demonstrate the activity of 1202 in Hodgkin’s lymphoma cell lines as a single agent as well as in combination with rituximab and anti-CD 30 conjugated monoclonal antibody approved for patients with Hodgkin’s lymphoma … |
|
Gilead Sciences, Inc. (GILD): Gilead Five-year Revenue Outlook, Part 1
Seeking Alpha … submitted a NDA to the FDA for marketing approval to support the use of Idelalisib, for the treatment of indolent non-Hodgkin’s lymphoma for patients with refractory iNHL (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. |
DAZ.online |
Screening vor Rituximab-Behandlung
DAZ.online In Verbindung mit dem monoklonalem Antikörper Rituximab (MabThera®) sind in der klinischen Praxis Fälle einer Hepatitis-B-Reaktivierung einschließlich fulminanter Hepatitis mit tödlichem Ausgang aufgetreten. Daher wurden die Empfehlungen bezüglich … |
Orencia Slows Proteinuria in Renal DiseaseMedPage TodayThe accumulation of evidence led investigators to evaluate abatacept in five patients with FSGS and nephrotic-range proteinuria. Four patients had recurrent FSGS that had demonstrated resistance to…